Top

Published in:

11-10-2023 | Parkinson's Disease | Review Article

Differentiating progressive supranuclear palsy from other movement disorders using transcranial sonography: a systematic review and meta-analysis

Authors: Yafei Wen, Hui Zhou, Mengwen Xia, Qianqian Liu, Hongzhi Quan, Liangjuan Fang

Published in: Neurological Sciences | Issue 2/2024

Abstract

Progressive supranuclear palsy (PSP) is an atypical parkinsonism that presents with different phenotypes. There are still no validated diagnostic biomarkers for early diagnosis of PSP. Transcranial sonography (TCS) is a promising tool in the differential diagnosis of parkinsonian disorders; however, there are no systematic investigations about the application of TCS in PSP patients. Therefore, we performed a systematic review and meta-analysis to discuss the role of TCS in diagnosing PSP by systematically searching PubMed, Cochrane Library, Chinese National Knowledge Infrastructure and Wan Fang databases. Of 66 obtained records, 16 articles, including 366 patients with PSP, were included. Our results showed the estimated random-effects pooled prevalence of substantia nigra hyperechogenicity in patients with PSP was 22% (95% CI 12–32%), lenticular nucleus hyperechogenicity was 70% (95% CI 52–82%), and enlarged third ventricle was 71% (95% CI 55–85%). Additionally, a normal echogenicity substantia nigra in TCS showed 70% sensitivity (95% CI 56–81%) and 86% specificity (95% CI 75–86%) to differentiate PSP from Parkinson’s disease. In conclusion, TCS is an important supplementary biomarker for diagnosing PSP. At the same time, the diagnostic value of TCS in discriminating PSP from other atypical parkinsonism and between different PSP phenotypes needs further exploration.

Lukic MJ, Respondek G, Kurz C et al (2022) Long-Duration Progressive Supranuclear Palsy: Clinical Course and Pathological Underpinnings. Ann Neurol 92:637–649. https://doi.org/10.1002/ana.26455CrossRefPubMed

Kovacs GG, Lukic MJ, Irwin DJ et al (2020) Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol 140:99–119. https://doi.org/10.1007/s00401-020-02158-2CrossRefPubMedPubMedCentral

Giagkou N, Hoglinger GU, Stamelou M (2019) Progressive supranuclear palsy. Int Rev Neurobiol 149:49–86. https://doi.org/10.1016/bs.irn.2019.10.013CrossRefPubMed

Respondek G, Stamelou M, Kurz C et al (2014) The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 29:1758–1766. https://doi.org/10.1002/mds.26054CrossRefPubMed

Höglinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 32:853–864. https://doi.org/10.1002/mds.26987CrossRefPubMedPubMedCentral

Ali F, Martin PR, Botha H et al (2019) Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. Mov Disord 34:1144–1153. https://doi.org/10.1002/mds.27619CrossRefPubMedPubMedCentral

Armstrong MJ (2018) Progressive Supranuclear Palsy: an Update. Curr Neurol Neurosci Rep 18:12. https://doi.org/10.1007/s11910-018-0819-5CrossRefPubMed

Coughlin DG, Litvan I (2020) Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism Relat Disord 73:105–116. https://doi.org/10.1016/j.parkreldis.2020.04.014CrossRefPubMedPubMedCentral

Alster P, Madetko N, Koziorowski D et al (2020) Progressive Supranuclear Palsy-Parkinsonism Predominant (PSP-P)-A Clinical Challenge at the Boundaries of PSP and Parkinson's Disease (PD). Front Neurol 11:180. https://doi.org/10.3389/fneur.2020.00180CrossRefPubMedPubMedCentral

10.

Stamelou M, Giagkou N, Höglinger GU (2019) One decade ago, one decade ahead in progressive supranuclear palsy. Mov Disord 34:1284–1293. https://doi.org/10.1002/mds.27788CrossRefPubMed

11.

Picillo M, Tepedino MF, Abate F et al (2020) Midbrain MRI assessments in progressive supranuclear palsy subtypes. J Neurol Neurosurg Psychiatry 91:98–103. https://doi.org/10.1136/jnnp-2019-321354CrossRefPubMed

12.

Shafieesabet A, Fereshtehnejad SM, Shafieesabet A et al (2017) Hyperechogenicity of substantia nigra for differential diagnosis of Parkinson's disease: A meta-analysis. Parkinsonism Relat Disord 42:1–11. https://doi.org/10.1016/j.parkreldis.2017.06.006CrossRefPubMed

13.

Becker G, Seufert J, Bogdahn U et al (1995) Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 45:182–184. https://doi.org/10.1212/wnl.45.1.182CrossRefPubMed

14.

Mei YL, Yang J, Wu ZR et al (2021) Transcranial Sonography of the Substantia Nigra for the Differential Diagnosis of Parkinson's Disease and Other Movement Disorders: A Meta-Analysis. Parkinsons Dis 2021:8891874. https://doi.org/10.1155/2021/8891874CrossRefPubMedPubMedCentral

15.

Richter D, Katsanos AH, Schroeder C et al (2019) Lentiform Nucleus Hyperechogenicity in Parkinsonian Syndromes: A Systematic Review and Meta-Analysis with Consideration of Molecular Pathology. Cells 9. https://doi.org/10.3390/cells9010002

16.

Heim B, Peball M, Hammermeister J et al (2022) Differentiating Parkinson's Disease from Essential Tremor Using Transcranial Sonography: A Systematic Review and Meta-Analysis. J Parkinsons Dis 12:1115–1123. https://doi.org/10.3233/JPD-213012CrossRefPubMedPubMedCentral

17.

Bouwmans AEP, Vlaar AMM, Srulijes K et al (2010) Transcranial sonography for the discrimination of idiopathic Parkinson's disease from the atypical parkinsonian syndromes. Int Rev Neurobiol 90:121–146. https://doi.org/10.1016/S0074-7742(10)90009-3

18.

Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https://doi.org/10.1136/bmj.b2535CrossRefPubMedPubMedCentral

19.

Whiting PF, Rutjes AWS, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536. https://doi.org/10.7326/0003-4819-155-8-201110180-00009CrossRefPubMed

20.

Hellwig S, Reinhard M, Amtage F et al (2014) Transcranial sonography and [18F]fluorodeoxyglucose positron emission tomography for the differential diagnosis of parkinsonism: a head-to-head comparison. Eur J Neurol 21:860–866. https://doi.org/10.1111/ene.12394CrossRefPubMed

21.

Liboni W, Pignatta P, Salzedo E et al (2011) Ultrasonography and MR Imaging in Progressive Supranuclear Palsy. Neuroradiol J 24:221–225. https://doi.org/10.1177/197140091102400209CrossRefPubMed

22.

Gaenslen A, Unmuth B, Godau J et al (2008) The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. The Lancet Neurology 7:417–424. https://doi.org/10.1016/s1474-4422(08)70067-xCrossRefPubMed

23.

Walter U, Niehaus L, Probst T et al (2003) Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 60:74–77. https://doi.org/10.1212/wnl.60.1.74CrossRefPubMed

24.

Walter U, Dressler D, Wolters A et al (2004) Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 63:504–509. https://doi.org/10.1212/01.wnl.0000133006.17909.32CrossRefPubMed

25.

Walter U, Dressler D, Probst T et al (2007) Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch Neurol 64:1635–1640. https://doi.org/10.1001/archneur.64.11.1635CrossRefPubMed

26.

Behnke S, Berg D, Naumann M et al (2005) Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry 76:423–425. https://doi.org/10.1136/jnnp.2004.049221CrossRefPubMedPubMedCentral

27.

Okawa M, Miwa H, Kajimoto Y et al (2007) Transcranial sonography of the substantia nigra in Japanese patients with Parkinson's disease or atypical parkinsonism: clinical potential and limitations. Intern Med 46:1527–1531. https://doi.org/10.2169/internalmedicine.46.0271CrossRefPubMed

28.

Ebentheuer J, Canelo M, Trautmann E et al (2010) Substantia nigra echogenicity in progressive supranuclear palsy. Mov Disord 25:773–777. https://doi.org/10.1002/mds.22981CrossRefPubMed

29.

Kostić VS, Mijajlović M, Smajlović D et al (2013) Transcranial brain sonography findings in two main variants of progressive supranuclear palsy. Eur J Neurol 20:552–557. https://doi.org/10.1111/ene.12034CrossRefPubMed

30.

Sastre-Bataller I, Vázquez JF, Martínez-Torres I et al (2013) Mesencephalic area measured by transcranial sonography in the differential diagnosis of parkinsonism. Parkinsonism Relat Disord 19:732–736. https://doi.org/10.1016/j.parkreldis.2013.04.010CrossRefPubMed

31.

Bartova P, Kraft O, Bernatek J et al (2014) Transcranial sonography and (123)I-FP-CIT single photon emission computed tomography in movement disorders. Ultrasound Med Biol 40:2365–2371. https://doi.org/10.1016/j.ultrasmedbio.2014.05.014CrossRefPubMed

32.

Sadowski K, Serafin-Król M, Szlachta K et al (2015) Basal ganglia echogenicity in tauopathies. J Neural Transm (Vienna) 122:863–865. https://doi.org/10.1007/s00702-014-1310-3CrossRefPubMed

33.

Sanzaro E, Iemolo F (2016) Transcranial sonography in movement disorders: an interesting tool for diagnostic perspectives. Neurol Sci 37:373–376. https://doi.org/10.1007/s10072-015-2424-6CrossRefPubMed

34.

Fujita H, Suzuki K, Numao A et al (2016) Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson's Disease and Atypical Parkinsonian Syndromes. PLoS One 11:e0165869. https://doi.org/10.1371/journal.pone.0165869CrossRefPubMedPubMedCentral

35.

Alonso-Canovas A, Tembl Ferrairó JI, Martínez-Torres I et al (2019) Transcranial sonography in atypical parkinsonism: How reliable is it in real clinical practice? A multicentre comprehensive study. Parkinsonism Relat Disord 68:40–45. https://doi.org/10.1016/j.parkreldis.2019.09.032CrossRefPubMed

36.

Ghourchian S, Mousavi A, Zamani B et al (2019) Midbrain area for differentiating Parkinson's disease from progressive supranuclear palsy. Clin Neurol Neurosurg 183:105383. https://doi.org/10.1016/j.clineuro.2019.105383CrossRefPubMed

37.

Tian J, Liu H, Zhang M, et al. (2020) The value of TCS, SWI and MRI in identifying progressive supranuclear palsy and Parkinson’s disease. J Apoplexy and Nervous Diseases 37, 895-899. https://doi.org/10.19845/j.cnki.zfysjjbzz.2020.0479

38.

Wang LS, Yu TF, Chai B et al (2021) Transcranial sonography in differential diagnosis of Parkinson disease and other movement disorders. Chin Med J (Engl) 134:1726–1731. https://doi.org/10.1097/cm9.0000000000001503CrossRefPubMed

39.

Pilotto A, Yilmaz R, Berg D (2015) Developments in the role of transcranial sonography for the differential diagnosis of parkinsonism. Curr Neurol Neurosci Rep 15:43. https://doi.org/10.1007/s11910-015-0566-9CrossRefPubMed

40.

Whitwell JL, Hoglinger GU, Antonini A et al (2017) Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord 32:955–971. https://doi.org/10.1002/mds.27038CrossRefPubMedPubMedCentral

41.

He L, Wu DF, Zhang JH et al (2022) Factors affecting transtemporal window quality in transcranial sonography. Brain Behav 12:e2543. https://doi.org/10.1002/brb3.2543CrossRefPubMedPubMedCentral

42.

Liang P, Shi L, Chen N et al (2015) Construction of brain atlases based on a multi-center MRI dataset of 2020 Chinese adults. Sci Rep:5. https://doi.org/10.1038/srep18216

43.

Garcia-Malo C, Novo-Ponte S, Castro-Villacanas Farzamnia A et al (2021) Correlation between systemic iron parameters and substantia nigra iron stores in restless legs syndrome. Sleep Med 85:191–195. https://doi.org/10.1016/j.sleep.2021.07.027CrossRefPubMed

44.

Lee S, Martinez-Valbuena I, de Andrea CE et al (2022) Cell-specific dysregulation of iron and oxygen homeostasis as a novel pathophysiology in PSP. Ann Neurol. https://doi.org/10.1002/ana.26540

Title: Differentiating progressive supranuclear palsy from other movement disorders using transcranial sonography: a systematic review and meta-analysis
Authors: Yafei Wen
Hui Zhou
Mengwen Xia
Qianqian Liu
Hongzhi Quan
Liangjuan Fang
Publication date: 11-10-2023
Publisher: Springer International Publishing
Keywords: Parkinson's Disease
Movement Disorder
Progressive Supranuclear Palsy
Atypical Parkinsonism
Published in: Neurological Sciences / Issue 2/2024
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-023-07107-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Differentiating progressive supranuclear palsy from other movement disorders using transcranial sonography: a systematic review and meta-analysis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2024

Functional propriospinal myoclonus in neuroleptic malignant syndrome

FLAIR hyperintense lesions with U-fiber and subcortical enhancement (FUSE) in MOG antibody-associated cerebral cortical encephalitis

Cerebral infarction in Behçet’s syndrome caused by obliterative focal arteritis

Neuronal intermediate filament autoimmunity manifesting as ataxia and peripheral neuropathy: a case report and literature review

Quality control in treating patients with patent foramen ovale: 7-year-experience of the Heart and Brain team of the Careggi University Hospital

Changing the stroke network during pandemic scenarios does not affect the management of patients with a positive Cincinnati prehospital stroke scale